FDA inspectors have come down hard on a drugmaker in Taiwan, issuing a warning letter to Taiwan Three Mast Pharmaceutical in Tainan City for serious manufacturing violations.
Taiwan's TOT Biopharm has opened in mainland China the first phase of what it says is a $100 million plant for developing and manufacturing cancer drugs for the global market.
Parexel International is adding another academic partner to its list of overseas collaborators, inking a deal with the National Taiwan University Hospital to provide drug development services in the country.
The Taiwanese government has recently been touting the country as a perfect environment for medical device companies targeting emerging markets, and Swissray International, maker of imaging devices, would seem to agree. The Switzerland-headquartered company is planning to expand into the country.
While medical device companies are increasingly targeting mainland China for investment and M&A opportunities, they should also pay close attention to Taiwan. The island's Central News Agency reports that Taiwan's government is making its own concerted effort to nurture industry growth in five different sectors.
Taiwan's FDA is warning providers across the island that they may be using counterfeit medical equipment, following the seizure of thousands of unlicensed plates and screws distributed by a Taipei medical device company.
Taiwanese CMO ScinoPharm is looking to cash in on Vivus' diet drug, signing on to manufacture one of the pill's APIs.
ScinoPharm is investing NT$1.1 billion ($37.6 million) in the construction of a plant in Tainan, Taiwan. The purpose of the plant: to produce injectable cancer drugs, according to the CMO.
A study conducted by GBI Research predicts that CMO outsourcing in Asia will generate $60 billion in revenues by 2018.
Chiltern, an international contract research organization, landed a legal entity in Taiwan, enabling it to conduct clinical trial services in the island nation.